Table 1.

50% Effective dose of oHSV in GBM and non-GBM cell lines

MOI (×10−3), 95% Confidence intervals
	rHSVQ		NG34
	ED50	R-Seq	ED50	R-Seq
U251	22.67 – 47.63	0.8947	2.620 – 5.436	0.8728
U2OS	15.11 – 41.57	0.7516	7.172 – 15.90	0.8516
G9Rluc	34.63 – 70.44	0.9173	4.827 – 7.922	0.9587
G30	9.439 – 16.87	0.9392	1.962 – 3.150	0.9588
G83	25.08 – 54.51	0.9028	4.424 – 9.737	0.8810
G326	17.87 – 43.33	0.8850	3.564 – 7.058	0.9237
G528	86.39 – 270.7	0.6973	26.66 – 64.31	0.8706

NOTE: Enhanced glioma cytotoxicity effect with GADD34-encoding γ₁34.5-null NG34 versus original γ₁34.5-null rHSVQ virus. Intracellular ATP was measured 3 days after oHSV infection with either rHSVQ or NG34 or rQNestin34.5 in GBM (U251, G9Rluc and G30) and non-GBM (U2OS) cells at 20,000 cells per a well of 96-well plates for cell viability assay. Data with three replicates were normalized with maximum and minimum values before calculating ranges of 50% effective doses (ED50) and values of R² at 95% confidence intervals. These plots with nonlinear dose–response curves are also provided in Supplementary Fig. S1.